A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)
Completed
Afferent Pharmaceuticals, Inc.
Phase 2
This is a randomised, double-blind, placebo-controlled, crossover, single centre study of
gefapixant (AF-219/MK-7264) in participants with idiopathic or treatment resistant chronic
cough designed to evaluate the effectiveness of gefapixant in reducing daytime objective
cough frequency.
A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee
Completed
Afferent Pharmaceuticals, Inc.
Phase 2
The purpose of this study is to assess the efficacy of a single dose level of gefapixant
(AF-219/MK-7264) in subjects with moderate to severe pain associated with osteoarthritis (OA)
of the knee compared with placebo after 4 weeks of treatment.
The study will also assess the safety and tolerability, changes in physical function,
stiffness, treatment response and health outcomes.
The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)
Terminated
Afferent Pharmaceuticals, Inc.
Phase 2
The purpose of this study is to assess the efficacy of gefapixant (AF-219/MK-7264) in female
participants with moderate to severe pain associated with interstitial cystitis/bladder pain
syndrome (IC/BPS) after 4 weeks of treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
